Clinical trials: Extensive Stage Small Cell Lung Carcinoma
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
Small Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory.
- Trial name
- NCT06780137
- Testing
- Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab
- Where
- 48 sites in United States, Argentina and 10 more
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
SCLC,Extensive Stage
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated…
- Trial name
- NCT05595460
- Testing
- RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- RayzeBio, Inc.
Small Cell Lung Cancer
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with extensive-stage small cell lung cancer.
- Trial name
- NCT05924841
- Testing
- BL-B01D1, SI-B003
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Merkel Cell Carcinoma, Small Cell Lung Cancer
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in participants with metastatic Merkel cell…
- Trial name
- NCT04590781
- Testing
- XmAb18087, XmAb18087 ± Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Xencor, Inc.
Small Cell Lung Cancer
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and…
- Trial name
- DeLLphi-315 (NCT07778316)
- Testing
- Tarlatamab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 400 people
- Sponsor
- Amgen
Lung Cancer
BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BBR 3464 in treating patients who have metastatic small…
- Trial name
- NCT00014547
- Testing
- BBR 3464
- Where
- 18 sites in United States
- Sponsor
- Theradex
Lung Cancer, Small Cell Lung Cancer
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
This trial is titled "A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC)." Part 1, the phase 1b portion of this study, is a…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- SCLC (NCT00791154)
- Testing
- AMG 479, Etoposide, AMG 102
- Volunteers
- 213 people
- Sponsor
- NantCell, Inc.
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites.
- Trial name
- NCT07895043
- Testing
- Alveltamig, Atezolizumab, ABBV-706
- Volunteers
- 80 people
- Sponsor
- AbbVie
Carcinoma, Small Cell
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch
- Trial name
- NCT04854590
- Where
- 18 sites in Japan
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab…
- Trial name
- CASPIAN (NCT03043872)
- Testing
- Durvalumab, Tremelimumab, Carboplatin
- Where
- 207 sites in United States, Argentina and 21 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
- Trial name
- TITANS (NCT07652736)
- Testing
- Tislelizumab
- Where
- 6 sites in Spain
- Volunteers
- 440 people
- Sponsor
- BeOne Medicines
Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the…
- Trial name
- NCT04924101
- Testing
- Pembrolizumab, MK-4830, Boserolimab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not…
- Trial name
- NCT07459634
- Testing
- Lurbinectedin, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jazz Pharmaceuticals
Small-cell Lung Cancer
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.
- Trial name
- NCT00286169
- Testing
- Amrubicin Hydrochloride
- Where
- 8 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Extensive-stage Small Cell Lung Cancer
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared…
- Trial name
- NCT04702880
- Testing
- BMS-986012, Carboplatin, Etoposide
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 135 people
- Sponsor
- Bristol-Myers Squibb
Extensive Small Cell Lung Cancer
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in subjects with extensive small cell lung cancer.
- Trial name
- NCT04234607
- Testing
- TQB2450, Anlotinib, Etoposide
- Where
- 26 sites in China
- Volunteers
- 738 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
- Trial name
- DeLLphi-305 (NCT06211036)
- Testing
- Tarlatamab, Durvalumab
- Where
- 219 sites in United States, Argentina and 27 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
- Trial name
- MERU (NCT03033511)
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 308 sites in United States, Australia and 39 more
- Volunteers
- 748 people
- Sponsor
- AbbVie
Small Cell Lung Cancer
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or…
- Trial name
- NCT00319969
- Testing
- Amrubicin, Topotecan
- Where
- 47 sites in United States
- Volunteers
- 76 people
- Sponsor
- Celgene Corporation